Mostrar el registro sencillo del ítem

dc.contributor.authorCarrillo Delgado, Esmeralda Esperanza 
dc.contributor.authorPrados Salazar, José Carlos 
dc.contributor.authorMarchal Corrales, Juan Antonio 
dc.contributor.authorBoulaiz Tassi, Houria 
dc.contributor.authorMartínez, Antonio
dc.contributor.authorRodríguez Serrano, Fernando 
dc.contributor.authorCaba Pérez, Octavio 
dc.contributor.authorSerrano Ortega, Salvio 
dc.contributor.authorAránega Jiménez, Antonia 
dc.date.accessioned2014-07-16T09:33:49Z
dc.date.available2014-07-16T09:33:49Z
dc.date.issued2006
dc.identifier.citationCarrillo, E.; et al. Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Disease Markers, 22(3): 175-181 (2006). [http://hdl.handle.net/10481/32689]es_ES
dc.identifier.issn0278-0240
dc.identifier.urihttp://hdl.handle.net/10481/32689
dc.description.abstractMalignant melanoma (MM) prognosis has been related to tumour thickness and clinical stage and metastasis risk has been associated with presence of tumour cells in peripheral blood. The aim of this study was to determine the relationship between presence of tyrosinase in peripheral blood of MM patients and their clinical prognosis. Blood samples from 58 MM patients (stage I–IV) were analysed, using RT-PCR assay to detect tyrosinase mRNA. The results showed that positive RT-PCR assay for tyrosinase were significantly associated with clinical status and tumour thickness. After a median follow-up of 24 months, RT-PCR results were found to be significant correlated with recurrence (p < 0.05) and clinical stage III (p < 0.05). Separate analysis of stage III tumours to determine the prognostic value of tyrosinase presence in peripheral blood showed an overall 24-month survival rate of 70% in the RT-PCR negative group versus 10% in the positive group (p < 0.02). These results suggest that detection of circulating melanoma cells may be especially relevant in stage III patients, in whom RT-PCR positivity defines a subpopulation at high risk of recurrence.es_ES
dc.description.sponsorshipThis study was supported by the Fondo de Investigación Sanitaria de la Seguridad Social (FIS), Spain through no. PI041372.es_ES
dc.language.isoenges_ES
dc.publisherHindawi Publishing Corporation; IOS Presses_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es_ES
dc.subjectPolymerase chain reactiones_ES
dc.subjectCirculating tumor cellses_ES
dc.subjectMessenger RNAes_ES
dc.subjectReverse transcriptasees_ES
dc.subjectMelanoma es_ES
dc.subjectCutaneous melanomaes_ES
dc.subjectResidual diseasees_ES
dc.subjectClinical stagees_ES
dc.subjectReaction assayes_ES
dc.subjectMarkeres_ES
dc.titlePrognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1155/2006/462065


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License